Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

In a study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for cardiovascular ...

In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for ...

Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online ...

In a report released today, Fabio Holscher from Warburg Research maintained a Buy rating on SAF-HOLLAND SE (0O4N – Research Report), with a price target of €25.00. The company’s shares ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

scientists at Eli Lilly & Company and Carelon Research conducted a retrospective study to elucidate the treatment patterns and real-world effectiveness of Tirzepatide in promoting weight loss ...

Tirzepatide combined with lifestyle modification reduced the highest number of obesity cases (45,609 per 100,000 eligible individuals), diabetes cases (20,854 per 100,000 eligible individuals ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

As research continues to explore their long-term safety and efficacy, semaglutide and tirzepatide could offer a meaningful shift in how T1D is managed—potentially bridging the gap between ...

1 This denial keeps in place the FDA’s declaratory order determining that the shortage of diabetes and weight-loss tirzepatide products has been resolved and phases out compounded tirzepatide ...